natgillin/translations-raw huggingface dataset:
No adverse reactions were observed following oral administration to puppies aged 8–9 weeks and weighing 2.0–3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (56 mg, 168 mg and 280 mg fluralaner/kg bodyweight) on three occasions at shorter intervals than recommended (8-week intervals).
Nisu se pokazale nikakve nuspojave prilikom peroralne primjene na štencima u starosti 8 do 9 tjedana i težine 2,0–3,6 kg, tretiranih 5 puta većim dozama od maksimalne preporučene doze (56 mg, 168 mg i 280 mg fluralanera/ kg tjelesne težine) u 3 navrata, s kraćim intervalima od preporučenog (8–tjedni intervali).
No adverse reactions were observed following topical administration to kitten aged 11-13 weeks and weighing 1.2-1.5 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg, 279 mg and 465 mg fluralaner/kg body weight) on three occasions at shorter intervals than recommended (8-week intervals).
Neškodljivost je dokazana kod mačića starosti 11 - 13 tjedana i težine 1,2 - 1,5 kg tretiranih trokratno s 5 x većim dozama od maksimalno preporučene doze (93 mg, 279 mg i 465 mg fluralanera/kg tjelesne mase) i u kraćim intervalima od preporučenih (8-tjedni intervali).
No adverse reactions were observed following topical administration to puppies aged 8–9 weeks and weighing 2.0–3.7 kg treated with overdoses of up to 5 times the maximum recommended dose (56 mg, 168 mg and 280 mg fluralaner/kg bodyweight) on three occasions at shorter intervals than recommended (8-week intervals).
Nisu uočene nikakve nuspojave prilikom primjene na koži, na štencima u starosti 8 do 9 tjedana i težine 2,0 – 3,7 kg, tretiranih 5 puta većim dozama od maksimalne preporučene doze (56 mg, 168 mg i 280 mg fluralanera/kg tjelesne težine) u 3 navrata, s kraćim intervalima od preporučenog (8–tjedni intervali).
No adverse reactions were observed in dogs aged 8 weeks and older, treated 8 times at 4 week intervals or 6 times at 2 week intervals, with 5 times the recommended dose.
Nema zabilježenih nuspojava kod pasa u dobi od 8 tjedana i starijih, tretiranih u intervalima od 8 puta u 4 tjedna ili intervalima od 6 puta u 2 tjedna, uz 5 puta preporučene doze.
No adverse reactions were observed in healthy Beagle puppies over 8 weeks of age when treated with 5 times the maximum dose repeated 6 times at intervals of 2-4 weeks.
Nepovoljne reakcije nisu zabilježene kod zdravih beagle štenaca u dobi od 8 tjedana starosti, kada se tretira s dozom pet puta većom od maksimalne doze, ponovljeno 6 puta u intervalima od 2 - 4 tjedana.
No adverse reactions were observed in healthy Beagle puppies over 8 weeks of age when treated with 5 times the maximum dose repeated 6 times at intervals of two to four weeks.
Nepovoljne reakcije nisu zabilježene kod zdravih beagle štenaca u dobi od 8 tjedana starosti, tretiranih s pet puta većom dozom od maksimalne doze, ponovljeno 6 puta u dvo-tjednim intervalima.
No adverse reactions, except those mentioned in the section “Adverse Reactions” were observed after the administration of a double dose of vaccine.
Nema nepovoljnih reakcija, nisu zapažene nakon davanja duple doze cjepiva, osim onih spomenutih u odlomku „Nepovoljne reakcije“
No adverse reactionts on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2 times the plasma AUC in humans at the maximum recommended human dose (MRHD).
U ženki i mužjaka štakora nisu primijećene nuspojave povezane s plodnošću ili reprodukcijom pri dozama koje uzrokuju plazmatsku izloženost (AUC) do približno 2 puta veće od plazmatske AUC pri najvišoj preporučenoj dozi u ljudi.
No AEs were reported following this event of trametinib overdose.
Nakon tog događaja predoziranja trametinibom nije prijavljen nijedan štetni događaj.
No age-specific differences in adverse reactions were observed between paediatric and adults subjects.
Nisu opažene razlike u nuspojavama između pedijatrijskih i odraslih ispitanika koje bi bile specifične za dob.
no AK lesion present, neither visible nor palpable
nema lezija aktiničke keratoze, niti vidljivih niti opipljivih
No ALT elevations ≥ 3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque psoriasis.
U ispitivanju faze III u kojem se Humira primjenjivala u pedijatrijskih bolesnika s plak psorijazom, nisu primijećena povišenja razine ALT-a ≥ 3 x GGN.
No ALT elevations ≥ 3 x ULN occurred in the Phase 3 trial of Humira in patients with polyarticular juvenile idiopathic arthritis who were 2 to <4 years.
Nije zabilježeno povišenje ALT-a ≥ 3 x GGN u ispitivanju faze III u kojem se Humira primjenjivala u bolesnika s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 2 do <4 godine.
No ALT elevations ≥3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque psoriasis.
U ispitivanju faze III u kojem se Humira primjenjivala u pedijatrijskih bolesnika s plak psorijazom, nisu primijećena povišenja razine ALT-a ≥ 3 x GGN.
No alteration of fertility was detected.
Nisu primijećene alteracije u plodnosti.
No amino acid substitutions associated with resistance to tenofovir disoproxil fumarate were identified in these isolates.
U tih izolata nisu utvrđene nikakve supstitucije aminokiselina povezane s rezistencijom na tenofovirdisoproksilfumarat.
No amino acid substitutions associated with resistance to tenofovir disoproxil fumarate were identified in these isolates.
U tih izolata nisu utvrđene nikakve supstitucije aminokiselina povezane s rezistencijom na tenofovirdizoproksilfumarat.
No amino acid substitutions associated with tenofovir disoproxil fumarate resistance were detected in any subject.
U nijednom ispitaniku nije zabilježena nikakva supstitucija aminokiselina povezana s rezistencijom na tenofovirdizoproksilfumarat.
No animal studies have been conducted to evaluate the genotoxic and carcinogenic potential of eculizumab or its effect on fertility.
Nisu provedena ispitivanja na životinjama kako bi se procijenio genotoksični i kancerogeni potencijal ekulizumaba ili njegovi učinci na plodnost.
No animal studies have been performed to determine potential effects on fertility in males or females.
Nisu provedena ispitivanja na životinjama kojima bi se utvrdili mogući učinci na plodnost mužjaka ili ženki.
No animal studies have been performed to establish the carcinogenic potential of daratumumab.
Nisu provedena ispitivanja na životinjama u svrhu utvrđivanja kancerogenog potencijala daratumumaba.
No animal toxicity studies were conducted with Cuprymina.
Nisu rađena toksikološka ispitivanja na životinjima za Cuprymina.
No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.
Nije bio opaţen antagonizam s emtricitabinom ili tenofoviralafenamidom kad su se kombinirali s drugim antiretrovirusnim lijekovima.
No antagonistic effects in vitro were seen with dolutegravir and other antiretrovirals (tested agents: stavudine, abacavir, efavirenz, nevirapine, lopinavir, amprenavir, enfuvirtide, maraviroc, adefovir and raltegravir).
Nisu primijećeni antagonistički učinci in vitro kod primjene dolutegravira i drugih antivirotika (ispitivani lijekovi: stavudin, abakavir, efavirenz, nevirapin, lopinavir, amprenavir, enfuvirtid, maravirok, adefovir i raltegravir).
No antagonistic effects in vitro were seen with dolutegravir and other antiretrovirals tested: stavudine, abacavir, efavirenz, nevirapine, lopinavir, amprenavir, enfuvirtide, maraviroc and raltegravir.
Nisu primijećeni antagonistički učinci in vitro kod primjene dolutegravira i drugih ispitivanih antiretrovirotika: stavudina, abakavira, efavirenza, nevirapina, lopinavira, amprenavira, enfuvirtida, maraviroka i raltegravira.
No anticoccidial substances or other agents having anticoccidial activity via feed or water should be used for at least 3 weeks following vaccination of the chickens.
Najmanje 3 tjedna nakon cijepljenja pilićima se ne smiju davati antikokcidijski veterinarsko- medicinski proizvodi ili bilo kakva druga sredstva koja imaju antikokcidijsku aktivnost.
No antiemetic treatment
bez antiemetičkog liječenja
No apparent association between the development of antibodies to ustekinumab and the development of injection site reactions was observed.
Nije primijećena očita povezanost razvoja protutijela na ustekinumab s nastankom reakcija na mjestu injekcije.
No apparent evidence of drug interaction was observed in 47 HIV-HCV co-infected patients who completed a 12 week pharmacokinetic substudy to examine the effect of ribavirin on the intracellular phosphorylation of some nucleoside reverse transcriptase inhibitors (lamivudine and zidovudine or stavudine).
U 47 bolesnika koinficiranih HIV-om i HCV-om nije jasno dokazana interakcija između lijekova tijekom 12-tjednog farmakokinetičkog podispitivanja učinaka ribavirina na unutarstaničnu fosforilaciju određenih nukleozidnih inhibitora reverzne transkriptaze (lamivudin i zidovudin ili stavudin).
no appetite for food
gubitak teka
No appreciable accumulation of ceftaroline is observed following multiple intravenous infusions of 600 mg administered over 60 minutes every 12 hours for up to 14 days in healthy adults with normal renal function.
Nije opaženo značajnije nakupljanje ceftarolina nakon višekratnih intravenskih infuzija od 600 mg, primijenjenih u trajanju od 60 minuta svakih 12 sati tijekom najdulje 14 dana u zdravih odraslih osoba s normalnom bubrežnom funkcijom.
No appreciable accumulation of ceftolozane/tazobactam is observed following multiple 1-hour IV infusions of 1 g / 0.5 g ceftolozane/tazobactam administered every 8 hours for up to 10 days in healthy adults with normal renal function.
Nije opaženo primjetno nakupljanje ceftolozana/tazobaktama nakon višestrukih jednosatnih intravenskih infuzija ceftolozana/tazobaktama u dozi od 1 g/0,5 g primjenjivanih svakih 8 sati u razdoblju do najviše 10 dana u zdravih odraslih osoba s normalnom funkcijom bubrega.
No appreciable accumulation of either saxagliptin or its major metabolite was observed with repeated once-daily dosing at any dose level.
Nije opaženo značajnije nakupljanje ni saksagliptina ni njegova glavnog metabolita kod višekratne primjene jedanput na dan u bilo kojoj dozi.
No arrhythmic events were reported in AURAex or AURA2 (see section 4.8).
U ispitivanjima AURAex i AURA2 nisu prijavljeni događaji aritmija (vidjeti dio 4.8).
No arrhythmic events were reported in AURAex or AURA2 (see sections 4.4 and 5.1).
Tijekom ispitivanja AURAex i AURA2 nisu prijavljeni događaji aritmija (vidjeti dijelove 4.4 i 5.1).
No back up contraception is needed.
Nije potrebno koristiti dodatnu kontracepciju.
No back-up contraception is needed.
Nije potrebno koristiti dodatnu metodu kontracepcije.
No beeps
Nema zvučnih signala
No benefit was observed for MACE or all cause mortality .
Nije primijećena korist s obzirom na pojavu MACE ili smrti zbog bilo kojeg uzroka.
No benefit was observed for MACE or all cause mortality.
Nije primijećena korist s obzirom na pojavu MACE ili smrti zbog bilo kojeg uzroka.
No benefit, attributable to Extavia, in quality of life (as measured by FAMS – Functional Assessment of MS: Treatment Outcomes Index) was seen.
Nije uočena nikakva korist koja bi se mogla pripisati Extaviji za kvalitetu života (mjerenu prema Funkcionalnoj procjenu multiple skleroze: Indeks ishoda liječenja).
No benefit, attributable to immediate Betaferon treatment, in quality of life (as measured by FAMS - Functional Assessment of MS: Treatment Outcomes Index) was seen.
Nije zamijećena korist koja se može pripisati trenutnom liječenju lijekom Betaferon što se tiče kvalitete života (mjerena uz pomoć FAMS – Funkcionalne procjene multiple skleroze: Indeks ishoda liječenja).
No benefit, attributable to immediate Betaferon treatment, in quality of life (as measured by FAMS – Functional Assessment of MS: Treatment Outcomes Index) was seen.
Nije zamijećena korist koja se može pripisati trenutnom liječenju lijekom Betaferon što se tiče kvalitete života (mjerena uz pomoć FAMS – Funkcionalne procjene multiple skleroze: Indeks ishoda liječenja).
No bleeding episodes were experienced in 42% of subjects while on individualised prophylaxis and in 23% of subjects while on weekly prophylaxis.
Nije bilo nijedne epizode krvarenja u 42% ispitanika dok su primali individualiziranu profilaksu i u 23,0% ispitanika dok su primali tjednu profilaksu.
No bleeding episodes were experienced in 45.3% of subjects while on individualised prophylaxis and in 17.4% of subjects while on weekly prophylaxis.
Nije bilo nijedne epizode krvarenja u 45,3% ispitanika dok su primali individualiziranu profilaksu i u 17,4% ispitanika dok su primali tjednu profilaksu.
No bleeding episodes were experienced in 46.4% of paediatric subjects.
U 46,4% pedijatrijskih ispitanika nije bilo nijedne epizode krvarenja.
No Blue Box included
Ne sadrži plavi okvir
no Blue Box included
nije uključen plavi okvir
No breakpoint for Brachyspira hyodysenteriae has been established.
Za bakteriju Brachyspira hyodysenteriae nije utvrđena točka promjene.
No cabozantinib-treated subjects in this study had a confirmed QTcF >500 ms, nor did any cabozantinib-treated subjects in the RCC study (at a dose of 60 mg).
Nijedan od ispitanika koji su primali kabozantinib u ovom ispitivanju nije imao QTcF >500 ms, kao i niti jedan od ispitanika koji su primali kabozantinib u ispitivanju RCC-a (pri dozi od 60 mg).
No carcinogenic studies have been conducted with cysteamine bitartrarte gastro-resistant hard capsules.
Nisu provedena ispitivanja kancerogenosti sa želučanootpornim tvrdim kapsulama cisteamin bitartrata.
No carcinogenicity and reproductive toxicology studies have been performed with flutemetamol (18F).
S flutemetamolom (18F) nisu provođene studije kancerogenosti i reproduktivne toksikologije.
No carcinogenicity studies have been performed with ONIVYDE.
Nisu provedena ispitivanja kancerogenosti s lijekom ONIVYDE.
No case of overdose has been reported for VEPACEL.
Nisu prijavljeni slučajevi predoziranja VEPACELOM.
No case of overdose has been reported within the approved indication.
Nisu prijavljeni slučajevi predoziranja unutar odobrene indikacije.
No case of overdose has been reported, and is unlikely to occur after ocular administration.
Nije prijavljen nijedan slučaj predoziranja, i nije vjerojatno da će se pojaviti nakon okularne primjene.
No case of overdose in adults or paediatrics has been reported.
Nema prijavljenih slučajeva predoziranja u odraslih bolesnika ili pedijatrijske populacije.
No case of overdose of Aldurazyme has been reported.
Nisu prijavljeni slučajevi predoziranja lijekom Aldurazyme.
No case of RPLS was reported in this study, but RPLS has been reported in other clinical studies.
U ovom ispitivanju nije bilo zabilježenih slučajeva RPLS, ali je pojava RPLS-a bila zabilježena u drugim kliničkim ispitivanjima.
No cases of cancer caused by Xofigo have been reported in clinical trials with a follow-up of up to three years.
U kliničkim ispitivanjima tijekom praćenja u trajanju do tri godine nije zabilježen nijedan slučaj raka prouzročenog lijekom Xofigo.
No cases of CAP due to MRSA were enrolled into the studies.
U ispitivanja nije bio uključen niti jedan slučaj izvanbolnički stečene pneumonije čiji je uzročnik bila MRSA.
No cases of ILD-like events have been reported with ONIVYDE therapy in clinical studies.
U kliničkim ispitivanjima nije zabilježen niti jedan događaj nalik na IBP.
No cases of interstitial lung diseases (ILD) have been reported with teriflunomide in the clinical trials.
Tijekom primjene teriflunomida u kliničkim ispitivanjima nisu prijavljeni slučajevi intersticijske bolesti pluća.
No cases of overdose after cutaneous use of Mirvaso were reported during the clinical development program.
Nisu prijavljeni slučajevi predoziranja nakon primijene lijeka Mirvaso na kožu tijekom kliničkog razvojnog programa.
No cases of overdose have been reported in clinical studies.
U kliničkim ispitivanjima nije bio zabilježen nijedan slučaj predoziranja.
No cases of overdose have been reported in patients with acquired haemophilia or Glanzmann’s thrombasthenia.
Nisu prijavljeni slučajevi predoziranja u bolesnika sa stečenom hemofilijom ili Glanzmannovom trombastenijom.
No cases of overdose with recombinant coagulation factor VIII have been reported.
Nije zabilježen niti jedan slučaj predoziranja rekombinantnim koagulacijskim faktorom VIII.
No cases of PML were reported in clinical studies of vedolizumab however, healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms as outlined in physician education materials, and consider neurological referral if they occur.
Nisu zabilježeni slučajevi PML u kliničkim ispitivanjima vedolizumaba, međutim zdravstveni djelatnici moraju u bolesnika koji primaju vedolizumab pratiti pojavu ili pogoršanje neuroloških znakova i simptoma kako je to opisano u edukativnim materijalima za liječnika, te uputiti bolesnika neurologu ako se oni pojave.
No cases of severe hypoglycaemia were observed
Nije zabilježen niti jedan slučaj teške hipoglikemije.
No cases of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis have been reported in the clinical development programme of tipranavir.
Nisu prijavljeni slučajevi Stevens- Johnsonovog sindroma ili toksične epidermalne nekrolize u premarketinškim kliničkim ispitivanjima s tipranavirom.
No cases of Torsades de Pointes or temporally related events suggestive of proarrhythmias occurred.
U tom vremenskom periodu nisu opaženi slučajevi Torsades de Pointes ili povezani događaji koji bi ukazivali na pojavu proaritmija.
No cases of Xofigo-induced cancer have been reported in clinical trials in follow-up of up to three years.
U kliničkim ispitivanjima tijekom praćenja u trajanju do tri godine nije zabilježen nijedan slučaj raka izazvanog lijekom Xofigo.
No cases of Xofigo-induced cancer have been reported in clinical trials in follow-up of up to three years.
U kliničkim ispitivanjima u praćenju do tri godine, nisu zabilježeni slučajevi raka induciranog lijekom Xofigo.
No cases were reported during clinical trials of avanafil (see section 4.4).
Tijekom kliničkih ispitivanja avanafila nije bilo prijavljenih slučajeva (vidjeti dio 4.4).
No cases were reported in patients in FAC arm .
U FAC skupini nije zabilježen niti jedan slučaj.
No cases were reported in patients in FAC arm.
U FAC skupini nije zabilježen niti jedan slučaj.
No cases were reported in patients in FAC.
U FAC skupini nije zabilježen niti jedan slučaj.
No cases with fatal outcome were reported in GIST, MRCC and pNET registrational studies.
U registracijskim kliničkim ispitivanjima GIST-a, MRCC-a i pNET-a nije zabilježen niti jedan slučaj sa smrtnim ishodom.
No change in dose is required for elderly patients.
Nije potrebna promjena doze kod starijih bolesnika.
No change in dose is required for elderly patients.
Nije potrebna promjena doze u starijih bolesnika.
No change in dose is required for patients with renal impairment.
Nije potrebna promjena doze u bolesnika s oštećenjem bubrega.
No change in dose is required for renal impairment.
Kod oštećenja bubrega nije potrebna promjena doze.
No change in dose or schedule.
Bez promjene doze ili rasporeda primjene
No change in plasma concentration were shown with paclitaxel concentrate.
Nisu uočene promjene u plazmatskoj koncentraciji pri primjeni koncentrata paklitaksela.
No change in starting dose is necessary.
Nije potrebna korekcija početne doze.
No change in starting dose is required in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2); dose titration should be done with caution in these patients (see section 4.4).
Nije potrebna promjena početne doze u bolesnika s teškim oštećenjem funkcije bubrega (procijenjena brzina glomerularne filtracije [eGFR] < 30 ml/min/1,73 m2); titraciju doze u ovih bolesnika treba provoditi oprezno (vidjeti dio 4.4).
No changes in methadone
Nisu bile tražene nikakve
No changes to lamivudine apparent clearance and volume of distribution, suggesting no induction effect of
Bez promjena vidljivog klirensa i volumena distribucije lamivudina što ukazuje na odsustvo indukcijskog učinka nevirapina na klirens lamivudina.
No children of less than 5 years of age were treated.
Nije liječeno nijedno dijete mlađe od 5 godina.
No cirrhosis
Bez ciroze
No cirrhosis With cirrhosis
bez ciroze sa cirozom
No cirrhosis**
Bez ciroze
No cirrhosisa
Bez cirozea
No cirrhosisc
Bez cirozec
No clear cutoff for PD-L1 expression can reliably be established when considering the relevant endpoints of tumour response and PFS.
Ne može se pouzdano ustanoviti jasna granična vrijednost za ekspresiju PD-L1 kada se razmatraju relevantne mjere ishoda u smislu tumorskog odgovora i PFS-a.
No clear evidence of a teratogenic effect was observed, however at toxic dose levels of telmisartan an effect on the postnatal development of the offsprings such as lower body weight and delayed eye opening was observed.
Ne postoje dokazi teratogenog učinka, ali studije na životinjama pokazale su potencijalni štetni učinak toksičnih doza telmisartana na postnatalni razvoj mladunčadi, kao što su manja tjelesna težina i odgođeno otvaranje očiju.
No clear relationship between renal function (as measured by creatinine clearance) and granisetron clearance was identified in population PK modelling.
Kod modeliranja populacijske farmakokinetike nisu utvrđene jasne poveznice između funkcije bubrega (mjerene klirensom kreatinina) i klirensa granisetrona.
No clear treatment-related effects or adverse effects were observed in reproductive toxicology studies in mice with a surrogate terminal complement inhibitory antibody.
Nisu primijećeni jasni učinci povezani s liječenjem niti nuspojave u ispitivanjima reprodukcijske toksičnosti na miševima pomoću zamjenskog inhibicijskog protutijela na terminalne komponente komplementa.
No clinical consequences were observed at dose levels of 3.7 times the recommended dose of Lymphoseek in humans, or at 390 times the anticipated human exposure of tilmanocept in animals.
Nisu zabilježene kliničke posljedice pri razinama doze 3,7 puta većima od preporučene doze lijeka Lymphoseek u ljudi, niti u životinja kod izloženosti tilmanoceptu 390 puta većoj od one očekivane u ljudi.
No clinical data are available on the use of afamelanotide in breastfeeding women.
Nema dostupnih kliničkih podataka o primjeni afamelanotidina u dojilja.
No clinical data are available, potential risk for human is unknown.
Nema dostupnih kliničkih podataka, potencijalni rizik za ljude je nepoznat.
No clinical data for safinamide on exposed pregnancies is available.
Nisu dostupni klinički podaci za izloženost safinamidu u trudnoći.
No clinical data on exposed pregnancies is available.
Nema dostupnih kliničkih podataka o izloženosti tijekom trudnoće.
No clinical data on the effects of Holoclar on fertility are available.
Nema dostupnih kliničkih podataka o učincima Holoclara na plodnost.
No clinical data on the need to adjust the dosage in patients with impaired hepatic or renal function are available (see section 4.4).
Nema dostupnih kliničkih podataka o potrebi prilagodbe doze u bolesnika s oštećenjem funkcije jetre ili bubrega (vidjeti dio 4.4.).
No clinical experience exists in patients with recurrent and previously treated BCCs, therefore use for previously treated tumours is not recommended.
Nema kliničkih iskustava u bolesnika s recidivirajućim i prethodno liječenim površinskim bazeocelularnim karcinomom kože, stoga se ne preporučuje uporaba za već liječene tumore.
No clinical experience exists with imiquimod cream immediately following treatment with other cutaneously applied drugs for treatment of external genital or perianal warts.
Ne postoji kliničko iskustvo u primjeni imikvimod kreme neposredno nakon provedenog liječenja vanjskih genitalnih i perianalnih bradavica drugim topikalnim lijekovima.
No clinical experience exists with the use of imiquimod cream in immunocompromised patients.
Nema kliničkih iskustava o primjeni imikvimod kreme u imunokompromitiranih bolesnika.
No clinical or animal data with insulin human on male or female fertility are available.
Nema dostupnih podataka iz kliničkih ispitivanja niti ispitivanja na životinjama o učinku humanog inzulina na plodnost u muškaraca i žena.